Opinion|Videos|October 28, 2024
Clinical Experience with Capivasertib
Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you share your clinical experience with capivasertib and your patient’s tolerability?
Advertisement
Related to this article
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5